Zyme Communications

@ZymeComms

We provide PR & services for the sector: follow for the latest news stories

Cambridge
Vrijeme pridruživanja: studeni 2010.

Tweetovi

Blokirali ste korisnika/cu @ZymeComms

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @ZymeComms

  1. . today announced it has joined the Entrepreneurial Programmes Initiative, which aims to promote the development of new business ventures within academia and encourage entrepreneurship.

    Poništi
  2. proslijedio/la je Tweet
    4. velj

    1 in 2 of us will get cancer in our lifetimes. We are Owlstone Medical & we are developing a for disease. Our platform is investigating new approaches for of cancer on breath

    Poništi
  3. 4. velj

    Enjoying the World Congress in London today, hearing about new deals and partnerships across , and facilitated at the event

    Poništi
  4. proslijedio/la je Tweet
    4. velj

    To mark World Cancer Day here is an interesting read on how “Cancer and rare diseases dominated 2019 drug approvals” Raising awareness of cancer and encouraging its prevention, detection, and treatment.

    Poništi
  5. 4. velj

    ., one of the world’s leading suppliers of reagents that enables research into and diagnostics for emerging and endemic , today announced the commercial release of its liquid format conjugation kits:

    Poništi
  6. proslijedio/la je Tweet
    4. velj

    is the most common cause of cancer death worldwide. Our team are committed to developing the best possible treatment for difficult tumours, together we will fight back against this awful disease

    Poništi
  7. proslijedio/la je Tweet
    4. velj

    Did you know 1 in 2 people in the UK will be diagnosed with cancer in their lifetime? At Start Codon, we are committed to empowering researchers and transforming pioneering science into life-saving therapies:

    Poništi
  8. proslijedio/la je Tweet
    4. velj

    Researchers at have used imaging mass cytometry to simultaneously quantify 35 biomarkers, resulting in high-dimensional pathology images of tumor tissue from 352 patients with . Published in -

    Poništi
  9. 3. velj

    Open Pharma Research Ltd today announced the introduction of the Congress USA, 19-20 May in , showcasing innovation in the . This follows the inaugural European last year. Find out more:

    Poništi
  10. 3. velj

    . today announced the appointments of Dr Catherine Beech OBE as Non-Executive Director and Dr Benedict Cross as Senior Director (Technology)

    Poništi
  11. 29. sij

    . launched its 2020 programme last week, this year exploring visions of the future. From mini organs in to life on Mars, it looks set to be interesting. We're glad to be based in a lively city for science!

    Poništi
  12. 28. sij

    . today announced the strengthening of production and customer service support for its scientific instrumentation and software, appointing Roy Eggleston, Tony Heywood, and John Forbes to its senior team:

    Poništi
  13. 28. sij

    . today announced that it has secured $1.1M of additional funding from to assess its regenerative therapy before entering clinical trials

    Poništi
  14. 28. sij

    . today announced that it has demonstrated initial proof-of-concept for its proprietary new class of drug conjugate, TMAC, in a pre-clinical animal model of cancer. The study showed that AVA04-VbP outperformed Bavencio, a marketed immunotherapy.

    Poništi
  15. 27. sij

    Our Managing Director Lorna Cuddon will be attending the World Congress in on the 4-5 February. Follow the link below to learn more about the and companies showcasing their work to and partners:

    Poništi
  16. 23. sij

    What makes and clusters like , and so successful? Read this analysis from for insight on how the growth of science hubs is shaping the UK's economy and geography:

    Poništi
  17. proslijedio/la je Tweet
    22. sij

    On this week's Careers in Discovery podcast, we were delighted to welcome , CEO of , entrepreneur, investor, and advisor to over 40 companies. Go to to hear Darrin's unique journey and his principles for success. Enjoy!

    Poništi
  18. 21. sij

    . today announced that it will license its GS knockout K1 cell line to to support the research and development of across multiple disease areas

    Poništi
  19. 21. sij

    From advances in and to the growing concerns over , the 2010s were a decade of rapid change. Check out the stories that shaped the past 10 years from :

    Poništi
  20. 21. sij

    . today announced a new multi-project collaboration with Otsuka Pharmaceutical, with an initial focus on applications

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·